Some Generics, Biosimilars Cut From Drug Pricing Provisions in Build Back Better Bill

The Senate Finance Committee has released amended Build Back Better Act text, which would exempt generics and biosimilars at risk of supply chain shortages from rebates drugmakers would have to pay to the government if they raise prices faster than the annual rate of inflation.
Source: Drug Industry Daily